HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

Lonza to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art...

Related Keywords

Guangzhou ,Guangdong ,China ,Sweden ,Australia ,Stockholm ,Sydney ,New South Wales ,Switzerland ,Singapore ,Swiss ,Martina Ribar Hestericov ,Dirk Oehlers ,Jeetendra Vaghjiani ,Jane Lowe ,Bryce Carmine ,Head Of External Communications ,Lonza Group Ltd ,European Hematology Association ,Swiss Exchange ,Haemalogix Ltd Haemalogi ,Haemalogix Ltd Contact Details ,Ir Department ,Haemalogix Ltd ,Singapore Exchange Securities Trading Limited ,Clinical Development Strategic Marketing ,Executive Director ,Clinical Development ,Strategic Marketing ,Swiss Alps ,Scientific Advisory Board ,Multiple Myeloma ,Group Ltd ,Sequential Cohort Study Comparing Kappamab Alone ,Low Dose Dexamethasone ,